哮喘新药显功效!tezepelumab将病情加重风险降低了56%

2021-02-27 Allan MedSci原创

TSLP靶向单克隆抗体tezepelumab已达到该试验的主要终点。

阿斯利康(AstraZeneca)和安进(Amgen)近日公布了III期NAVIGATOR研究的全部结果,研究结果表明,与安慰剂相比,在标准护理中加入tezepelumab可使重度、不受控制的哮喘患者的哮喘急性发作率(AAER)降低56%,且不论基线嗜酸性粒细胞计数如何。在两家公司去年11月宣布,TSLP靶向单克隆抗体tezepelumab已达到该试验的主要终点。

阿斯利康(AstraZeneca)生物制药研发部门负责人Mene Pangalos表示:“NAVIGATOR研究结果表明,tezepelumab能够显著减少哮喘急性发作频率。更为重要的是,无论患者基线嗜酸性粒细胞计数、过敏状态和呼出的一氧化氮(FeNO)如何,tezepelumab均有效”。

该试验招募了1059例12至80岁患有严重不受控制的哮喘患者,这些患者在52周内接受tezepelumab或安慰剂的皮下注射。在这些患者中,基线时血液嗜酸性粒细胞计数高和低的患者比例大致相等。

 

原始出处:

https://www.firstwordpharma.com/node/1804506?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1912556, encodeId=ba241912556e9, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun May 23 13:35:07 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820714, encodeId=71231820e1430, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Tue Aug 03 06:35:07 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799555, encodeId=0e351e9955583, content=<a href='/topic/show?id=e98ee086708' target=_blank style='color:#2F92EE;'>#病情加重#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70867, encryptionId=e98ee086708, topicName=病情加重)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Sep 10 16:35:07 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728845, encodeId=c9bd1e288456f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Sep 27 14:35:07 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956716, encodeId=6bdc956e163c, content=什么时候上市, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05215199555, createdName=1473763bm88暂无昵称, createdTime=Tue Apr 13 21:33:44 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765134, encodeId=8f2b1e6513434, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Jan 01 17:35:07 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598463, encodeId=84611598463d0, content=<a href='/topic/show?id=68c31e315bd' target=_blank style='color:#2F92EE;'>#Tezepelumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17315, encryptionId=68c31e315bd, topicName=Tezepelumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d3b18597603, createdName=surilei, createdTime=Mon Mar 01 02:35:07 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625848, encodeId=46d616258481a, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14019, encryptionId=bc29140196e, topicName=PEL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=399320916411, createdName=tidiq, createdTime=Mon Mar 01 02:35:07 CST 2021, time=2021-03-01, status=1, ipAttribution=)]
    2021-05-23 snf701207
  2. [GetPortalCommentsPageByObjectIdResponse(id=1912556, encodeId=ba241912556e9, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun May 23 13:35:07 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820714, encodeId=71231820e1430, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Tue Aug 03 06:35:07 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799555, encodeId=0e351e9955583, content=<a href='/topic/show?id=e98ee086708' target=_blank style='color:#2F92EE;'>#病情加重#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70867, encryptionId=e98ee086708, topicName=病情加重)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Sep 10 16:35:07 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728845, encodeId=c9bd1e288456f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Sep 27 14:35:07 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956716, encodeId=6bdc956e163c, content=什么时候上市, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05215199555, createdName=1473763bm88暂无昵称, createdTime=Tue Apr 13 21:33:44 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765134, encodeId=8f2b1e6513434, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Jan 01 17:35:07 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598463, encodeId=84611598463d0, content=<a href='/topic/show?id=68c31e315bd' target=_blank style='color:#2F92EE;'>#Tezepelumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17315, encryptionId=68c31e315bd, topicName=Tezepelumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d3b18597603, createdName=surilei, createdTime=Mon Mar 01 02:35:07 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625848, encodeId=46d616258481a, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14019, encryptionId=bc29140196e, topicName=PEL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=399320916411, createdName=tidiq, createdTime=Mon Mar 01 02:35:07 CST 2021, time=2021-03-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1912556, encodeId=ba241912556e9, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun May 23 13:35:07 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820714, encodeId=71231820e1430, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Tue Aug 03 06:35:07 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799555, encodeId=0e351e9955583, content=<a href='/topic/show?id=e98ee086708' target=_blank style='color:#2F92EE;'>#病情加重#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70867, encryptionId=e98ee086708, topicName=病情加重)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Sep 10 16:35:07 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728845, encodeId=c9bd1e288456f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Sep 27 14:35:07 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956716, encodeId=6bdc956e163c, content=什么时候上市, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05215199555, createdName=1473763bm88暂无昵称, createdTime=Tue Apr 13 21:33:44 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765134, encodeId=8f2b1e6513434, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Jan 01 17:35:07 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598463, encodeId=84611598463d0, content=<a href='/topic/show?id=68c31e315bd' target=_blank style='color:#2F92EE;'>#Tezepelumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17315, encryptionId=68c31e315bd, topicName=Tezepelumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d3b18597603, createdName=surilei, createdTime=Mon Mar 01 02:35:07 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625848, encodeId=46d616258481a, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14019, encryptionId=bc29140196e, topicName=PEL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=399320916411, createdName=tidiq, createdTime=Mon Mar 01 02:35:07 CST 2021, time=2021-03-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1912556, encodeId=ba241912556e9, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun May 23 13:35:07 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820714, encodeId=71231820e1430, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Tue Aug 03 06:35:07 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799555, encodeId=0e351e9955583, content=<a href='/topic/show?id=e98ee086708' target=_blank style='color:#2F92EE;'>#病情加重#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70867, encryptionId=e98ee086708, topicName=病情加重)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Sep 10 16:35:07 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728845, encodeId=c9bd1e288456f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Sep 27 14:35:07 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956716, encodeId=6bdc956e163c, content=什么时候上市, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05215199555, createdName=1473763bm88暂无昵称, createdTime=Tue Apr 13 21:33:44 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765134, encodeId=8f2b1e6513434, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Jan 01 17:35:07 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598463, encodeId=84611598463d0, content=<a href='/topic/show?id=68c31e315bd' target=_blank style='color:#2F92EE;'>#Tezepelumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17315, encryptionId=68c31e315bd, topicName=Tezepelumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d3b18597603, createdName=surilei, createdTime=Mon Mar 01 02:35:07 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625848, encodeId=46d616258481a, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14019, encryptionId=bc29140196e, topicName=PEL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=399320916411, createdName=tidiq, createdTime=Mon Mar 01 02:35:07 CST 2021, time=2021-03-01, status=1, ipAttribution=)]
    2021-09-27 feather89
  5. [GetPortalCommentsPageByObjectIdResponse(id=1912556, encodeId=ba241912556e9, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun May 23 13:35:07 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820714, encodeId=71231820e1430, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Tue Aug 03 06:35:07 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799555, encodeId=0e351e9955583, content=<a href='/topic/show?id=e98ee086708' target=_blank style='color:#2F92EE;'>#病情加重#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70867, encryptionId=e98ee086708, topicName=病情加重)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Sep 10 16:35:07 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728845, encodeId=c9bd1e288456f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Sep 27 14:35:07 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956716, encodeId=6bdc956e163c, content=什么时候上市, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05215199555, createdName=1473763bm88暂无昵称, createdTime=Tue Apr 13 21:33:44 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765134, encodeId=8f2b1e6513434, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Jan 01 17:35:07 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598463, encodeId=84611598463d0, content=<a href='/topic/show?id=68c31e315bd' target=_blank style='color:#2F92EE;'>#Tezepelumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17315, encryptionId=68c31e315bd, topicName=Tezepelumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d3b18597603, createdName=surilei, createdTime=Mon Mar 01 02:35:07 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625848, encodeId=46d616258481a, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14019, encryptionId=bc29140196e, topicName=PEL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=399320916411, createdName=tidiq, createdTime=Mon Mar 01 02:35:07 CST 2021, time=2021-03-01, status=1, ipAttribution=)]
    2021-04-13 1473763bm88暂无昵称

    什么时候上市

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1912556, encodeId=ba241912556e9, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun May 23 13:35:07 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820714, encodeId=71231820e1430, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Tue Aug 03 06:35:07 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799555, encodeId=0e351e9955583, content=<a href='/topic/show?id=e98ee086708' target=_blank style='color:#2F92EE;'>#病情加重#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70867, encryptionId=e98ee086708, topicName=病情加重)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Sep 10 16:35:07 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728845, encodeId=c9bd1e288456f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Sep 27 14:35:07 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956716, encodeId=6bdc956e163c, content=什么时候上市, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05215199555, createdName=1473763bm88暂无昵称, createdTime=Tue Apr 13 21:33:44 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765134, encodeId=8f2b1e6513434, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Jan 01 17:35:07 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598463, encodeId=84611598463d0, content=<a href='/topic/show?id=68c31e315bd' target=_blank style='color:#2F92EE;'>#Tezepelumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17315, encryptionId=68c31e315bd, topicName=Tezepelumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d3b18597603, createdName=surilei, createdTime=Mon Mar 01 02:35:07 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625848, encodeId=46d616258481a, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14019, encryptionId=bc29140196e, topicName=PEL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=399320916411, createdName=tidiq, createdTime=Mon Mar 01 02:35:07 CST 2021, time=2021-03-01, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1912556, encodeId=ba241912556e9, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun May 23 13:35:07 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820714, encodeId=71231820e1430, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Tue Aug 03 06:35:07 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799555, encodeId=0e351e9955583, content=<a href='/topic/show?id=e98ee086708' target=_blank style='color:#2F92EE;'>#病情加重#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70867, encryptionId=e98ee086708, topicName=病情加重)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Sep 10 16:35:07 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728845, encodeId=c9bd1e288456f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Sep 27 14:35:07 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956716, encodeId=6bdc956e163c, content=什么时候上市, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05215199555, createdName=1473763bm88暂无昵称, createdTime=Tue Apr 13 21:33:44 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765134, encodeId=8f2b1e6513434, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Jan 01 17:35:07 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598463, encodeId=84611598463d0, content=<a href='/topic/show?id=68c31e315bd' target=_blank style='color:#2F92EE;'>#Tezepelumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17315, encryptionId=68c31e315bd, topicName=Tezepelumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d3b18597603, createdName=surilei, createdTime=Mon Mar 01 02:35:07 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625848, encodeId=46d616258481a, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14019, encryptionId=bc29140196e, topicName=PEL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=399320916411, createdName=tidiq, createdTime=Mon Mar 01 02:35:07 CST 2021, time=2021-03-01, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1912556, encodeId=ba241912556e9, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun May 23 13:35:07 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820714, encodeId=71231820e1430, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Tue Aug 03 06:35:07 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799555, encodeId=0e351e9955583, content=<a href='/topic/show?id=e98ee086708' target=_blank style='color:#2F92EE;'>#病情加重#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70867, encryptionId=e98ee086708, topicName=病情加重)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Fri Sep 10 16:35:07 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728845, encodeId=c9bd1e288456f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Sep 27 14:35:07 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956716, encodeId=6bdc956e163c, content=什么时候上市, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05215199555, createdName=1473763bm88暂无昵称, createdTime=Tue Apr 13 21:33:44 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765134, encodeId=8f2b1e6513434, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Jan 01 17:35:07 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598463, encodeId=84611598463d0, content=<a href='/topic/show?id=68c31e315bd' target=_blank style='color:#2F92EE;'>#Tezepelumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17315, encryptionId=68c31e315bd, topicName=Tezepelumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d3b18597603, createdName=surilei, createdTime=Mon Mar 01 02:35:07 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625848, encodeId=46d616258481a, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14019, encryptionId=bc29140196e, topicName=PEL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=399320916411, createdName=tidiq, createdTime=Mon Mar 01 02:35:07 CST 2021, time=2021-03-01, status=1, ipAttribution=)]
    2021-03-01 tidiq

相关资讯

Mol Med Rep:circARRDC3促进白细胞介素-13诱导的鼻腔上皮细胞炎症细胞因子和粘液的产生

过敏性鼻炎(AR)是一种常见的鼻黏膜炎症。它是哮喘发病的主要风险因素,且AR控制不佳可导致哮喘症状加重,影响患者的生活质量和生产效率。

Respir Res:母乳喂养时间能够改变新生儿和家族风险因素对儿童哮喘和过敏的影响

儿童哮喘和过敏性疾病是一个严重的全球性问题。关于分娩方式、家庭中孩子的数量和母乳喂养与儿童哮喘和过敏性疾病的关联性发现并不一致。最近,有研究人员评估了这些关联,并调查了母乳喂养是否改变了新生儿和家族性

J Allergy Clin Immunol Pract:Dupilumab可改善中重度特应性皮炎成人的哮喘和鼻窦炎疗效

在中重度特应性皮炎(AD)患者的临床试验中,Dupilumab具有疗效,且安全性可接受。最近,有研究人员在4项随机、双盲、安慰剂对照试验中评估了Dupilumab对中度至重度AD成年患者哮喘和鼻窦状况

Clin Exp Allergy:季节性过敏性鼻炎患者下呼吸道中IL-33表达增加且与天然过敏原暴露无关

在过敏性哮喘患者中,参与2型气道炎症发展的IL-33通路被激活。根据 "同一气道,同一疾病 "的概念,IL-33通路在过敏性鼻炎患者的气道中也应被激活。

Eur Arch Otorhinolaryngol:哮喘和鼻炎患者中鼻腔通畅度与口面肌功能变化的关系

最近,有研究人员确定了口面肌功能变化与鼻腔通畅性的关系。

拓展阅读

独家揭秘!射干麻黄汤如何战胜哮喘:长春中医大破解千年古方奥秘

SMD能降低炎性因子如IgE、CRP、IL-4、IL-6,减轻OVA诱导的肺组织病理变化。同时,SMD能抑制MyD88/IKK/NF-κB信号通路,是其治疗哮喘的重要机制。

JAMA子刊:生命早期暴露于空气污染与儿童哮喘累积发病率

生命早期的空气污染与儿童早期和中期哮喘发病率增加相关,特别是在城市社区中生活、面临较少机会和资源以及多重环境共同暴露的边缘化家庭中风险更高。

World Allergy Organ J:现实世界中成年哮喘患者的慢性鼻窦炎诊断生物标志物有哪些?

研究人员开发了生物标志物来预测成年哮喘患者的 CRS。结果发现,periostin、DPP10 和 AERD 表型是预测成人哮喘患者 CRS 的重要生物标志物。

ATVB 中国医学科学院基础医学研究所赵红梅/王婧教授团队与北京协和医院刘暴教授、北京医院安琦教授揭示哮喘加重动脉粥样硬化新机制

研究揭示了经IgE刺激后的肥大细胞通过“外泌体-环RNA CDR1as-内皮细胞”途径介导哮喘加重动脉粥样硬化的机制,为哮喘合并动脉粥样硬化人群的干预提供了新思路。

WJO:胎儿肺部生长可用于预测儿童期呼吸道感染和哮喘的风险

研究表明,超声监测胎儿肺部生长可以预测儿童早期呼吸道感染和哮喘的风险。

夜班麻醉遭遇术中哮喘发作,一起学习一下临床表现以及处置

对采用区域麻醉或肌松药者如果出现通气困难,需要鉴别是支气管痉挛引起,还是呼吸肌紧张或咳嗽所致。